{
  "positions": [
    {
      "ticker": "OMER",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "compound_move": null,
      "category": "Biotech",
      "position": {
        "strike": 5.0,
        "expiration": "2026-02-20",
        "expiration_display": "Feb 20, 2026",
        "option_type": "CALL",
        "quantity": 10
      },
      "prices": {
        "entry": 1.91,
        "current": 8.05,
        "stock_price": 12.08,
        "break_even": 6.91,
        "max_buy": 4.23,
        "pnl_pct": 321.5
      },
      "entry_zone": {
        "zone": "passed",
        "color": "red",
        "message": "Up 321.5% - wait for pullback",
        "pct_from_entry": 321.46596858638753
      },
      "enr": {
        "enr": 28.9,
        "win_prob": 91.0,
        "enr_zone": {
          "zone": "avoid",
          "color": "red",
          "message": "Negative expected return"
        },
        "research_found": false,
        "is_live": true
      },
      "cont": {
        "score": 70,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2025-12-24",
        "date_display": "Dec 24, 2025",
        "event": "PDUFA APPROVED",
        "drug": "Narsoplimab/Yartemlia - TA-TMA (FDA APPROVED Dec 24, 2025)",
        "days_to_catalyst": -33
      },
      "timing": {
        "days_to_expiry": 25,
        "entry_date": "2025-12-31 07:14:59"
      },
      "thesis": {
        "drug_name": "Narsoplimab/Yartemlia - TA-TMA (FDA APPROVED Dec 24, 2025)",
        "indication": "PDUFA APPROVED",
        "highlights": [],
        "risks": [],
        "is_first_in_class": null,
        "is_orphan": null,
        "is_fast_track": null,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-25T08:54:10.813812",
      "recommendation": {
        "action": "EXIT",
        "notes": "This was a great win for me and i trimmed multiple times some before the PDUFA and still hold a small amount.  waiting for a better exit price or I may convert to stocks for a long term hold and avoid more short term gains.  A good problem for a well ITM option.  ",
        "updated": "2026-01-24T09:45:15.602877"
      }
    },
    {
      "ticker": "RGNX",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "compound_move": null,
      "category": "Biotech",
      "position": {
        "strike": 12.5,
        "expiration": "2026-04-17",
        "expiration_display": "Apr 17, 2026",
        "option_type": "CALL",
        "quantity": 20
      },
      "prices": {
        "entry": 4.325,
        "current": 4.4,
        "stock_price": 14.01,
        "break_even": 16.825,
        "max_buy": 3.58,
        "pnl_pct": 1.7
      },
      "entry_zone": {
        "zone": "good",
        "color": "green",
        "message": "Within 1.7% of entry - still good",
        "pct_from_entry": 1.7341040462427681
      },
      "enr": {
        "enr": 91.1,
        "win_prob": 93.4,
        "enr_zone": {
          "zone": "weak",
          "color": "orange",
          "message": "Below target threshold"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 90,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-02-08",
        "date_display": "Feb 08, 2026",
        "event": "PDUFA",
        "drug": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "days_to_catalyst": 13
      },
      "timing": {
        "days_to_expiry": 81,
        "entry_date": "2025-12-31 07:15:01"
      },
      "thesis": {
        "drug_name": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "indication": "PDUFA",
        "highlights": [
          "RGNX presents a legitimate high-probability approval opportunity for RGX-121, a first-in-class gene therapy for Hunter syndrome. The regulatory pathway is clean: FDA inspections complete with zero observations, no safety concerns raised, and accelerated approval alignment. The PRV optionality provid..."
        ],
        "risks": [
          "No options meet 140% ENR threshold - paying 30-50% premium over fair value",
          "28% run-up suggests approval partially priced; limited upside vs. downside",
          "Denali competition (DNL310 PDUFA April 5) creates binary outcome for market share"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-25T08:54:11.250229",
      "recommendation": {
        "action": "HOLD",
        "notes": "Well same comments as my $15 strikes here but this one is in the money and i'm goign to let it ride past the PDUFA.  - I've had this one for a while now but it hasn't moved much.  not much ENR left but my continuation score tells me this will run after approval.  I expect it will still move.  as of 1/23/26  i don't now i would get in here but  i have plenty of expiration time to hold past the PDUFA approval and OI is still increasing.",
        "updated": "2026-01-23T21:42:36.795094"
      }
    },
    {
      "ticker": "RGNX",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "compound_move": null,
      "category": "Biotech",
      "position": {
        "strike": 15.0,
        "expiration": "2026-04-17",
        "expiration_display": "Apr 17, 2026",
        "option_type": "CALL",
        "quantity": 20
      },
      "prices": {
        "entry": 4.6,
        "current": 3.8499999999999996,
        "stock_price": 14.01,
        "break_even": 19.6,
        "max_buy": 2.59,
        "pnl_pct": -16.3
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 16.3% from entry - better value",
        "pct_from_entry": -16.30434782608696
      },
      "enr": {
        "enr": 59.3,
        "win_prob": 84.7,
        "enr_zone": {
          "zone": "weak",
          "color": "orange",
          "message": "Below target threshold"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 90,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-02-08",
        "date_display": "Feb 08, 2026",
        "event": "PDUFA",
        "drug": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "days_to_catalyst": 13
      },
      "timing": {
        "days_to_expiry": 81,
        "entry_date": "2026-01-08 12:29:03"
      },
      "thesis": {
        "drug_name": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "indication": "PDUFA",
        "highlights": [
          "RGNX presents a legitimate high-probability approval opportunity for RGX-121, a first-in-class gene therapy for Hunter syndrome. The regulatory pathway is clean: FDA inspections complete with zero observations, no safety concerns raised, and accelerated approval alignment. The PRV optionality provid..."
        ],
        "risks": [
          "No options meet 140% ENR threshold - paying 30-50% premium over fair value",
          "28% run-up suggests approval partially priced; limited upside vs. downside",
          "Denali competition (DNL310 PDUFA April 5) creates binary outcome for market share"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-25T08:54:11.564244",
      "recommendation": {
        "action": "HOLD",
        "notes": " I've had this one for a while now but it hasn't moved much.  not much ENR left but my continuation score tells me this will run after approval.  I expect it will still move.  as of 1/23/26  i don't now i would get in here but  i have plenty of expiration time to hold past the PDUFA approval and OI is still increasing.",
        "updated": "2026-01-24T09:46:38.409105"
      }
    },
    {
      "ticker": "VNDA",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "compound_move": null,
      "category": "Biotech",
      "position": {
        "strike": 6.0,
        "expiration": "2026-03-20",
        "expiration_display": "Mar 20, 2026",
        "option_type": "CALL",
        "quantity": 10
      },
      "prices": {
        "entry": 1.675,
        "current": 2.075,
        "stock_price": 8.0672,
        "break_even": 7.675,
        "max_buy": 2.13,
        "pnl_pct": 23.9
      },
      "entry_zone": {
        "zone": "caution",
        "color": "yellow",
        "message": "Up 23.9% - consider smaller size",
        "pct_from_entry": 23.880597014925375
      },
      "enr": {
        "enr": 150.3,
        "win_prob": 87.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": -40,
        "rating": "LOW",
        "display": "Low (Exit Early)"
      },
      "catalyst": {
        "date": "2026-02-21",
        "date_display": "Feb 21, 2026",
        "event": "PDUFA",
        "drug": "Bysanti (milsaperidone) - Bipolar I & Schizophrenia (NEREUS approved 12/30/25)",
        "days_to_catalyst": 26
      },
      "timing": {
        "days_to_expiry": 53,
        "entry_date": "2025-12-31 07:15:00"
      },
      "thesis": {
        "drug_name": "Bysanti (milsaperidone) - Bipolar I & Schizophrenia (NEREUS approved 12/30/25)",
        "indication": "PDUFA",
        "highlights": [
          "VNDA presents a compelling multi-catalyst thesis for a 2026 LEAP: Bysanti PDUFA (Feb 21), imsidolimab PDUFA (~mid-2026), and NEREUS launch traction all captured in Dec 2026 expiration. The 1,931 OI at the $10 strike suggests institutional/retail conviction, and light insider buying is a rare positiv..."
        ],
        "risks": [
          "140% bid-ask spread makes entry/exit treacherous",
          "62% run-up means good news largely priced in",
          "Jan 7 HETLIOZ CRL shows FDA willing to reject Vanda applications"
        ],
        "is_first_in_class": 0,
        "is_orphan": 0,
        "is_fast_track": 0,
        "short_interest": 7.88
      },
      "oi": {
        "current": 5305,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "stable"
      },
      "last_updated": "2026-01-25T08:54:11.935636",
      "recommendation": {
        "action": "HOLD",
        "notes": "ok this is a hold that I've had for some time.  but plan to start reducing prior to the PDUFA date.   High chance of sell the news.  I'm up quite a bit but it shows there is still ENR left.  Not sure i would buy now (wait for my new recommendations) , but your call on this one.",
        "updated": "2026-01-24T09:51:39.404821"
      }
    },
    {
      "ticker": "GOSS",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": true,
      "compound_move": 130.8,
      "category": "Biotech",
      "position": {
        "strike": 5.0,
        "expiration": "2027-01-15",
        "expiration_display": "Jan 15, 2027",
        "option_type": "CALL",
        "quantity": 60
      },
      "prices": {
        "entry": 1.15,
        "current": 1.25,
        "stock_price": 2.7062,
        "break_even": 6.15,
        "max_buy": 0.27,
        "pnl_pct": 8.7
      },
      "entry_zone": {
        "zone": "good",
        "color": "green",
        "message": "Within 8.7% of entry - still good",
        "pct_from_entry": 8.69565217391306
      },
      "enr": {
        "enr": -27.4,
        "win_prob": 35.2,
        "enr_zone": {
          "zone": "avoid",
          "color": "red",
          "message": "Negative expected return"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 105,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-02-28",
        "date_display": "Feb 28, 2026",
        "event": "Phase 3",
        "drug": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "days_to_catalyst": 33
      },
      "timing": {
        "days_to_expiry": 354,
        "entry_date": "2025-12-31 07:14:59"
      },
      "thesis": {
        "drug_name": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "indication": "Phase 3",
        "highlights": [
          "GOSS presents a compelling contrarian LEAP opportunity with institutional validation via the concentrated 4,339 OI on the $3 Jan-2027 strike. The structural setup is textbook: proven management (Hasnain sold Receptos for $7.2B), heavy insider buying at $1.14-$1.82, first-in-class mechanism with comb..."
        ],
        "risks": [
          "Phase 2 TORREY missed 6MWD endpoint - same endpoint used in Phase 3 PROSERA",
          "Merck Winrevair first-mover advantage in PAH market with $238K/year pricing",
          "Enriched FC II/III patient strategy relies on subgroup signal that may not replicate"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 0,
        "short_interest": 3.6
      },
      "oi": {
        "current": 5042,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "stable"
      },
      "last_updated": "2026-01-25T08:54:12.259366",
      "recommendation": {
        "action": "HOLD",
        "notes": "I've had this position for a while and  its a hold for me.  But I don't recommend getting in ",
        "updated": "2026-01-24T10:44:23.735435"
      }
    },
    {
      "ticker": "GOSS",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": true,
      "compound_move": 130.8,
      "category": "Biotech",
      "position": {
        "strike": 3.0,
        "expiration": "2027-01-15",
        "expiration_display": "Jan 15, 2027",
        "option_type": "CALL",
        "quantity": 50
      },
      "prices": {
        "entry": 1.4,
        "current": 1.7,
        "stock_price": 2.7062,
        "break_even": 4.4,
        "max_buy": 0.87,
        "pnl_pct": 21.4
      },
      "entry_zone": {
        "zone": "caution",
        "color": "yellow",
        "message": "Up 21.4% - consider smaller size",
        "pct_from_entry": 21.42857142857144
      },
      "enr": {
        "enr": 39.8,
        "win_prob": 68.5,
        "enr_zone": {
          "zone": "avoid",
          "color": "red",
          "message": "Negative expected return"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 105,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-02-28",
        "date_display": "Feb 28, 2026",
        "event": "Phase 3",
        "drug": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "days_to_catalyst": 33
      },
      "timing": {
        "days_to_expiry": 354,
        "entry_date": "2026-01-07 13:19:27"
      },
      "thesis": {
        "drug_name": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "indication": "Phase 3",
        "highlights": [
          "GOSS presents a compelling contrarian LEAP opportunity with institutional validation via the concentrated 4,339 OI on the $3 Jan-2027 strike. The structural setup is textbook: proven management (Hasnain sold Receptos for $7.2B), heavy insider buying at $1.14-$1.82, first-in-class mechanism with comb..."
        ],
        "risks": [
          "Phase 2 TORREY missed 6MWD endpoint - same endpoint used in Phase 3 PROSERA",
          "Merck Winrevair first-mover advantage in PAH market with $238K/year pricing",
          "Enriched FC II/III patient strategy relies on subgroup signal that may not replicate"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 0,
        "short_interest": 3.6
      },
      "oi": {
        "current": 5042,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "stable"
      },
      "last_updated": "2026-01-25T08:54:12.592331",
      "recommendation": {
        "action": "HOLD",
        "notes": "This ENR has dropped some since purchase so only accumulate on pull backs.  watch the max buy.  Sometimes i still get in if it is a little below my 140% criteria.  This has a high continuation score but may expire prior to full PDUFA approval.  We may roll some of these over time.   ",
        "updated": "2026-01-24T10:37:33.640194"
      }
    },
    {
      "ticker": "IMMP",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "compound_move": null,
      "category": "Biotech",
      "position": {
        "strike": 2.5,
        "expiration": "2026-07-17",
        "expiration_display": "Jul 17, 2026",
        "option_type": "CALL",
        "quantity": 30
      },
      "prices": {
        "entry": 0.9,
        "current": 1.0,
        "stock_price": 3.18,
        "break_even": 3.4,
        "max_buy": 1.72,
        "pnl_pct": 11.1
      },
      "entry_zone": {
        "zone": "caution",
        "color": "yellow",
        "message": "Up 11.1% - consider smaller size",
        "pct_from_entry": 11.111111111111116
      },
      "enr": {
        "enr": 320.6,
        "win_prob": 71.5,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 55,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-03-31",
        "date_display": "Mar 31, 2026",
        "event": "Phase 3 Data readout",
        "drug": null,
        "days_to_catalyst": 64
      },
      "timing": {
        "days_to_expiry": 172,
        "entry_date": "2026-01-21"
      },
      "thesis": {
        "drug_name": null,
        "indication": "Phase 3 Data readout",
        "highlights": [
          "IMMP presents a compelling long-term biotech investment case - the Phase 2 INSIGHT-003 data showing 32.9-month mOS vs 22.0-month historical benchmark is genuinely impressive, the Dr. Reddy's $369M total deal value validates the asset, and efti's differentiated MHC Class II mechanism is scientificall..."
        ],
        "risks": [
          "Catalyst date is FUTILITY ANALYSIS Q1 2026, NOT Phase 3 efficacy data",
          "All available options have >30% spreads = untradeable",
          "84% run-up suggests options premium already inflated"
        ],
        "is_first_in_class": 1,
        "is_orphan": 0,
        "is_fast_track": 1,
        "short_interest": 3.59
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "stable"
      },
      "last_updated": "2026-01-25T08:54:12.919822",
      "recommendation": {
        "action": "ACCUMULATE",
        "notes": "This is a new buy for me.  I love the set up .  ",
        "updated": "2026-01-23T21:43:57.689868"
      }
    },
    {
      "ticker": "CRMD",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "compound_move": null,
      "category": "Biotech",
      "position": {
        "strike": 8.0,
        "expiration": "2026-08-21",
        "expiration_display": "Aug 21, 2026",
        "option_type": "CALL",
        "quantity": 40
      },
      "prices": {
        "entry": 1.4,
        "current": 1.625,
        "stock_price": 7.28,
        "break_even": 9.4,
        "max_buy": 2.12,
        "pnl_pct": 16.1
      },
      "entry_zone": {
        "zone": "caution",
        "color": "yellow",
        "message": "Up 16.1% - consider smaller size",
        "pct_from_entry": 16.07142857142858
      },
      "enr": {
        "enr": 223.1,
        "win_prob": 68.5,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 90,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-06-30",
        "date_display": "Jun 30, 2026",
        "event": "Phase 3 Data readout",
        "drug": null,
        "days_to_catalyst": 155
      },
      "timing": {
        "days_to_expiry": 207,
        "entry_date": "2026-01-21"
      },
      "thesis": {
        "drug_name": null,
        "indication": "Phase 3 Data readout",
        "highlights": [],
        "risks": [],
        "is_first_in_class": 0,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": 21.63
      },
      "oi": {
        "current": 3173,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "stable"
      },
      "last_updated": "2026-01-25T08:54:13.237627",
      "recommendation": {
        "action": "ACCUMULATE",
        "notes": "New position this week.  Add but watch the max buy.  Make those market makers work for their money.  start with a bid close to the bid and work your way up.  Watch the spread and dont over pay.  if you get 80% of the way to the ask wait until close to close and see if they take your bid.  Good luck.",
        "updated": "2026-01-24T10:10:57.284559"
      }
    },
    {
      "ticker": "CRMD",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": true,
      "compound_move": 114.5,
      "category": "Biotech",
      "position": {
        "strike": 10.0,
        "expiration": "2027-01-15",
        "expiration_display": "Jan 15, 2027",
        "option_type": "CALL",
        "quantity": 40
      },
      "prices": {
        "entry": 1.41,
        "current": 1.275,
        "stock_price": 7.28,
        "break_even": 11.41,
        "max_buy": 1.54,
        "pnl_pct": -9.6
      },
      "entry_zone": {
        "zone": "good",
        "color": "green",
        "message": "Within -9.6% of entry - still good",
        "pct_from_entry": -9.57446808510638
      },
      "enr": {
        "enr": 205.7,
        "win_prob": 65.9,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "research_found": true,
        "is_live": true
      },
      "cont": {
        "score": 90,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-06-30",
        "date_display": "Jun 30, 2026",
        "event": "Phase 3 Data readout",
        "drug": null,
        "days_to_catalyst": 155
      },
      "timing": {
        "days_to_expiry": 354,
        "entry_date": "2026-01-23"
      },
      "thesis": {
        "drug_name": null,
        "indication": "Phase 3 Data readout",
        "highlights": [],
        "risks": [],
        "is_first_in_class": 0,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": 21.63
      },
      "oi": {
        "current": 1877,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "stable"
      },
      "last_updated": "2026-01-25T08:54:13.630781",
      "recommendation": {
        "action": "ACCUMULATE",
        "notes": "new position accumulate.  Remember start with a low bid and work your way up.  wait until close to the close to get the best price.  but if your within the max buy go for it add some.",
        "updated": "2026-01-24T10:41:55.242765"
      }
    }
  ],
  "summary": {
    "total_positions": 9,
    "total_value": 57225.0,
    "avg_days_to_catalyst": 51.0
  },
  "market_status": {
    "is_open": false,
    "last_updated": "2026-01-25T08:54:13.631188"
  },
  "last_updated": "2026-01-25T08:54:13.631197"
}